BioSpace News Archive

Liquid GPS® Successfully Launched in Q2

NOXXON Pharma N.V. (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it will host a Key Opinion Leader (KOL) event focused on novel treatment approaches for glioblastoma.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) (NYSE-MKT:AMPE).

Wasatch Midwifery and Wellness is now the very first birth center with national accreditation in Utah. It is the only accredited birth center for over 200 miles.

Dave Harris is a recently retired principle at PricewaterhouseCoopers (PwC)

Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019

Corporate Restructuring and Pipeline Focus Expected to Extend Cash Runway

OvaScienceSM reported financial results for the second quarter ended June 30, 2018 and provided an update on its review of strategic alternatives.

AURORA Phase III Trial in lupus nephritis anticipated to complete enrollment ahead of schedule

Announced a Cooperative Research and Development Agreement (CRADA) to collaborate with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology to fund a planned pivotal Phase 3 trial to evaluate uproleselan (GMI-1271) in older, newly diagnosed acute myeloid leukemia (AML) patients eligible for intensive chemotherapy